Androgen Function in the Pathophysiology and Treatment of Male Huntington's Disease Patients

被引:7
作者
Ransome, M. I. [1 ]
机构
[1] Univ Melbourne, Florey Neurosci Inst, Melbourne Brain Ctr, Parkville, Vic 3010, Australia
基金
英国医学研究理事会;
关键词
Huntington's disease; androgen; androgen receptor; hypogonadism; testosterone replacement therapy; gonadotrophic axis; GROWTH-FACTOR-I; RECEPTOR POLYMORPHISM; TESTOSTERONE THERAPY; DEPRESSIVE SYMPTOMS; DEPRIVATION THERAPY; PLASMA TESTOSTERONE; PROSTATE-CANCER; MOUSE MODEL; LATE-ONSET; BRAIN;
D O I
10.1111/j.1365-2826.2012.02347.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Low concentrations of circulating testosterone have been associated with dementia manifesting with advancing age and in neurodegenerative conditions. Huntingtons disease (HD) is a dominantly inherited neurodegenerative disease with an invariably fatal outcome. Severe motor symptoms, psychosis and dementia are symptomatic hallmarks of the progression of HD that result from the dysfunction and death of neocortical and basal ganglia neurones. Treatments are directed toward manifest symptoms, although they are largely ineffectual in slowing or preventing disease progression. Emerging data have identified hypothamic pathologies in HD that result in endocrine disturbances. Clinically defined primary or secondary hypogonadism elicit low circulating testosterone concentrations and have been linked to the development of Alzheimers disease in men. Examining similar neuroendocrine dysfunction in HD including the nature of manifest hypogonadism in male patients could allow an elucidation of the complex pathophysiology of HD and provide an impetus for hitherto untested testosterone replacement therapy.
引用
收藏
页码:1275 / 1283
页数:9
相关论文
共 50 条
  • [41] A review of the treatment options for Huntington's disease
    Bonelli, RM
    Hofmann, P
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (04) : 767 - 776
  • [42] International Guidelines for the Treatment of Huntington's Disease
    Bachoud-Levi, Anne-Catherine
    Ferreira, Joaquim
    Massart, Renaud
    Youssov, Katia
    Rosser, Anne
    Busse, Monica
    Craufurd, David
    Reilmann, Ralf
    De Michele, Giuseppe
    Rae, Daniela
    Squitieri, Ferdinando
    Seppi, Klaus
    Perrine, Charles
    Scherer-Gagou, Clarisse
    Audrey, Olivier
    Verny, Christophe
    Burgunder, Jean-Marc
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [43] Immunomodulatory Strategies for Huntington's Disease Treatment
    Colpo, Gabriela D.
    Rocha, Natalia P.
    Stimming, Erin Fur
    Teixeira, Antonio L.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2017, 16 (08) : 936 - 944
  • [44] Mitochondrial Respiratory Function in Peripheral Blood Cells from Huntington's Disease Patients
    Ehinger, Johannes K.
    Morota, Saori
    Hansson, Magnus J.
    Paul, Gesine
    Elmer, Eskil
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2016, 3 (05): : 472 - 482
  • [45] Rehabilitation in Huntington's Disease
    Rollnik, J. D.
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2015, 83 (06) : 334 - 343
  • [46] Neuroinflammation in Huntington's disease
    Moeller, Thomas
    JOURNAL OF NEURAL TRANSMISSION, 2010, 117 (08) : 1001 - 1008
  • [47] Potential biomarkers to follow the progression and treatment response of Huntington's disease
    Disatnik, Marie-Helene
    Joshi, Amit U.
    Saw, Nay L.
    Shamloo, Mehrdad
    Leavitt, Blair R.
    Qi, Xin
    Mochly-Rosen, Daria
    JOURNAL OF EXPERIMENTAL MEDICINE, 2016, 213 (12) : 2655 - 2669
  • [48] Dopamine and Huntington's disease
    Schwab, Laetitia C.
    Garas, Shaady N.
    Drouin-Ouellet, Janelle
    Mason, Sarah L.
    Stott, Simon R.
    Barker, Roger A.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (04) : 445 - 458
  • [49] Therapeutics in Huntington's Disease
    Killoran, Annie
    Biglan, Kevin M.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2012, 14 (02) : 137 - 149
  • [50] Huntington's Disease and Mitochondria
    Farshbaf, Mohammad Jodeiri
    Ghaedi, Kamran
    NEUROTOXICITY RESEARCH, 2017, 32 (03) : 518 - 529